Anyone with any experience in clinical trials knows that what happens in one is NO WHERE indicative of what will happen with something else that hasn't even been tested yet, is nothing like what that one trial just tested, and has no pathway to being tested any time soon if ever
It's what you would call snake oil salesmanship of trying to inflate a very suspect otc stock.
Checkpoint proteins, such as PD-L1 on tumor cells and PD-1 on T cells, help keep immune responses in check. The binding of PD-L1 to PD-1 keeps T cells from killing tumor cells in the body (left panel). Blocking the binding of PD-L1 to PD-1 with an immune checkpoint inhibitor (anti-PD-L1 or anti-PD-1) allows the T cells to kill tumor cells (right panel).